Page 147 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Imiquimod: physicians’ awareness, attitudes and experiences
9. Are you aware of the application of imiquimod (Aldara ) for vaginal intraepithelial neoplasia (VAIN), in literature or clinical practice? Have you ever applied imiquimod for this indication?
· I am aware of this, I have not applied it myself. (to question 22) · I am aware of this, I have applied it myself. (to question 10)
· I am not aware of this. (to question 22)
10. You have applied imiquimod in VAIN. How often have you applied it for this indication?
· · ·
11. What · · ·
1-5 times
6-10 times
More than 10 times
was(/were) the lesion grade(s)? Low grade lesion(s) (VAIN 1) High grade lesion(s) (VAIN 2-3) Both
12. Was it a primary or recurrent lesion? · Primary lesion(s)
· Recurrent lesion(s) · Both
13. What was your rationale for using imiquimod in the treatment of this lesion? (open question)
14. How did you apply the imiquimod? (multiple options possible) · Vaginal capsule
· Vaginal suppository · Vaginal tampon
· Vaginal applicator
· Other: ...
15. What was the dosing scheme and treatment period? (open question)
16. How did you evaluate treatment efficacy (multiple options possible) · Cytology only
· Colposcopy without biopsies · Colposcopy with biopsies
· Other: ...
17. Was treatment of the VAIN lesion(s) with imiquimod successful? (multiple options possible) · Yes: lesions regression, invasive treatment no longer necessary
· Yes: complete remission, invasive treatment no longer necessary
· No: persistent lesion
· No: progressive lesion
18. Which side effects did you notice in the patients who were treated with imiquimod for VAIN? (multiple options possible)
· Vaginal/vulvar pain
· Vulvar erythema
· Vulvar erosion/ulceration · Vaginal discharge
· Flu-like symptoms
· Other: ...
145
7